Analysts at StockNews.com assumed coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.
Other research analysts have also recently issued reports about the stock. Raymond James cut shares of Jounce Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, February 23rd. Sumitomo Mitsui Financial Group reissued a “neutral” rating on shares of Jounce Therapeutics in a report on Friday, February 24th. Finally, Piper Sandler downgraded Jounce Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, March 27th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Jounce Therapeutics presently has an average rating of “Hold” and an average target price of $6.00.
Jounce Therapeutics Price Performance
NASDAQ JNCE opened at $1.90 on Thursday. Jounce Therapeutics has a 12 month low of $0.58 and a 12 month high of $7.85. The company has a market capitalization of $99.07 million, a price-to-earnings ratio of -0.74 and a beta of 0.74. The firm’s fifty day moving average price is $1.30 and its 200 day moving average price is $1.42.
Insider Buying and Selling at Jounce Therapeutics
Hedge Funds Weigh In On Jounce Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. PFM Health Sciences LP raised its position in Jounce Therapeutics by 3.7% in the third quarter. PFM Health Sciences LP now owns 4,094,488 shares of the company’s stock worth $9,581,000 after acquiring an additional 144,820 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Jounce Therapeutics during the fourth quarter worth approximately $40,000. BNP Paribas Arbitrage SA grew its position in Jounce Therapeutics by 102.9% in the second quarter. BNP Paribas Arbitrage SA now owns 9,115 shares of the company’s stock worth $28,000 after buying an additional 4,623 shares during the last quarter. Balyasny Asset Management LLC bought a new position in shares of Jounce Therapeutics in the third quarter valued at $26,000. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of Jounce Therapeutics by 97.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 40,425 shares of the company’s stock valued at $45,000 after buying an additional 20,000 shares in the last quarter. 80.66% of the stock is owned by institutional investors.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.
Featured Stories
- Get a free copy of the StockNews.com research report on Jounce Therapeutics (JNCE)
- Penny Stock Wag! Group Co. Has Solid Sell-Side Support
- Staples Stocks Get Lift From Conagra Results, New Highs In Sight
- SGH Bottomed, But Can It Reverse And Move Higher?
- Is Pinterest Showing Signs of an Improving Ad Market?
- At 3x Earnings, Avis Budget Is Worth Taking for a Spin
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
